Voyager Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $40.4M | $80.0M | $250.0M | $40.9M | $37.4M | $171.1M | $104.4M | $7.6M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $134.7M | $127.4M | $92.2M | $60.8M | $73.8M | $108.8M | $119.7M | $64.9M |
| SG&A Expense | $37.5M | $35.9M | $35.8M | $31.0M | $37.2M | $35.0M | $36.3M | $33.8M |
| Operating Income | $-131.8M | $-83.3M | $122.0M | $-50.8M | $-73.6M | $27.4M | $-51.7M | $-91.1M |
| Operating Margin | -326.6% | -104.1% | 48.8% | -124.3% | -196.8% | 16.0% | -49.5% | -1,195.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-119.6M | $-64.3M | $133.7M | $-46.4M | $-71.2M | $36.7M | $-43.6M | $-88.5M |
| Income Tax Expense | $144.0K | $665.0K | $1.4M | $16.0K | — | — | — | $-180.0K |
| Net Income | $-119.7M | $-65.0M | $132.3M | $-46.4M | $-71.2M | $36.7M | $-43.6M | $-88.3M |
| Net Margin | -296.5% | -81.3% | 52.9% | -113.4% | -190.3% | 21.5% | -41.8% | -1,158.8% |
| EPS (Basic) | $-2.04 | $-1.13 | $3.08 | $-1.21 | $-1.89 | $0.99 | $-1.21 | $-2.75 |
| EPS (Diluted) | $-2.04 | $-1.13 | $2.97 | $-1.21 | $-1.89 | $0.98 | $-1.21 | $-2.75 |
| Shares Outstanding (Basic) | 58.7M | 57.7M | 43.0M | 38.4M | 37.7M | 37.1M | 35.9M | 32.1M |
| Shares Outstanding (Diluted) | 58.7M | 57.7M | 44.6M | 38.4M | 37.7M | 37.3M | 35.9M | 32.1M |
| Dividends Per Share | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 |